OBJECTIVE: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. DESIGN: Multisite, randomized, double-blind, placebo-controlled clinical trial. SETTING: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. PATIENT(S): A total of 205 midlife women (46% African-American) who met criteria participated. INTERVENTION(S): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). MAIN OUTCOME MEASURE(S): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. RESULT(S): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. CONCLUSION(S): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. CLINICAL TRIAL REGISTRATION NUMBER: NCT00894543.
OBJECTIVE: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. DESIGN: Multisite, randomized, double-blind, placebo-controlled clinical trial. SETTING: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. PATIENT(S): A total of 205 midlife women (46% African-American) who met criteria participated. INTERVENTION(S): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). MAIN OUTCOME MEASURE(S): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. RESULT(S): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. CONCLUSION(S): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. CLINICAL TRIAL REGISTRATION NUMBER: NCT00894543.
Authors: Eila Suvanto-Luukkonen; Riitta Koivunen; Helena Sundström; Risto Bloigu; Eija Karjalainen; Leena Häivä-Mällinen; Juha S Tapanainen Journal: Menopause Date: 2005 Jan-Feb Impact factor: 2.953
Authors: Janet S Carpenter; Anna Maria Storniolo; Shelley Johns; Patrick O Monahan; Faouzi Azzouz; Julie L Elam; Cynthia S Johnson; Richard C Shelton Journal: Oncologist Date: 2007-01
Authors: Gary Elkins; Joel Marcus; Vered Stearns; Michelle Perfect; M Hasan Rajab; Christopher Ruud; Lynne Palamara; Timothy Keith Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Gabriel Rada; Daniel Capurro; Tomas Pantoja; Javiera Corbalán; Gladys Moreno; Luz M Letelier; Claudio Vera Journal: Cochrane Database Syst Rev Date: 2010-09-08
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335
Authors: William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter Journal: CA Cancer J Clin Date: 2013-01-25 Impact factor: 508.702
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: Nancy Fugate Woods; Chancellor Hohensee; Janet S Carpenter; Lee Cohen; Kristine Ensrud; Ellen W Freeman; Katherine A Guthrie; Hadine Joffe; Andrea Z LaCroix; Julie L Otte Journal: Menopause Date: 2016-02 Impact factor: 3.310
Authors: Andrea Z LaCroix; Ellen W Freeman; Joseph Larson; Janet S Carpenter; Hadine Joffe; Susan D Reed; Katherine M Newton; Rebecca A Seguin; Barbara Sternfeld; Lee Cohen; Kristine E Ensrud Journal: Maturitas Date: 2012-09-30 Impact factor: 5.110